IL237836A - Pde9i with imidazo pyrazinone backbone - Google Patents
Pde9i with imidazo pyrazinone backboneInfo
- Publication number
- IL237836A IL237836A IL237836A IL23783615A IL237836A IL 237836 A IL237836 A IL 237836A IL 237836 A IL237836 A IL 237836A IL 23783615 A IL23783615 A IL 23783615A IL 237836 A IL237836 A IL 237836A
- Authority
- IL
- Israel
- Prior art keywords
- imidazo
- methyl
- pyrazin
- azetidin
- fluorophenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011001692 | 2011-10-10 | ||
| PCT/EP2012/069936 WO2013053690A1 (en) | 2011-10-10 | 2012-10-09 | Pde9i with imidazo pyrazinone backbone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL237836A true IL237836A (en) | 2017-07-31 |
Family
ID=47019007
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL237836A IL237836A (en) | 2011-10-10 | 2015-03-19 | Pde9i with imidazo pyrazinone backbone |
| IL253448A IL253448A0 (en) | 2011-10-10 | 2017-07-12 | Pde91 is an imidazo- pyrazinone backbone |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL253448A IL253448A0 (en) | 2011-10-10 | 2017-07-12 | Pde91 is an imidazo- pyrazinone backbone |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9643970B2 (OSRAM) |
| EP (2) | EP2906562B1 (OSRAM) |
| JP (1) | JP2015531401A (OSRAM) |
| CN (2) | CN106905324B (OSRAM) |
| AU (2) | AU2012323085B2 (OSRAM) |
| BR (1) | BR112015007731B1 (OSRAM) |
| CA (1) | CA2886885C (OSRAM) |
| HK (1) | HK1211023A1 (OSRAM) |
| IL (2) | IL237836A (OSRAM) |
| IN (1) | IN2015DN02829A (OSRAM) |
| MA (1) | MA37958B1 (OSRAM) |
| MX (2) | MX381326B (OSRAM) |
| SG (1) | SG11201502728WA (OSRAM) |
| TN (1) | TN2015000100A1 (OSRAM) |
| WO (1) | WO2013053690A1 (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2015DN02829A (OSRAM) * | 2011-10-10 | 2015-09-11 | Lundbeck & Co As H | |
| CR20160395A (es) | 2014-02-13 | 2016-12-20 | Incyte Corp | Ciclopropilaminas como inhibidores de lsd1 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| ES2672797T3 (es) | 2014-02-13 | 2018-06-18 | Incyte Corporation | Ciclopropilaminas como inhibidores de LSD1 |
| MY183499A (en) | 2014-02-13 | 2021-02-22 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| US9695168B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| TW201629064A (zh) | 2014-10-10 | 2016-08-16 | Ｈ 朗德貝克公司 | 作爲ｐｄｅ１抑制劑之三唑並吡酮 |
| MA51438A (fr) | 2015-04-03 | 2021-04-14 | Incyte Corp | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 |
| JO3627B1 (ar) * | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| EP4335497A3 (en) * | 2015-07-07 | 2024-05-01 | H. Lundbeck A/S | Pde9 inhibitor with imidazo pyrazinone backbone for treatment of peripheral diseases |
| TW201717948A (zh) * | 2015-08-10 | 2017-06-01 | Ｈ 朗德貝克公司 | 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療 |
| SG10202001219UA (en) | 2015-08-12 | 2020-03-30 | Incyte Corp | Salts of an lsd1 inhibitor |
| JP6877423B2 (ja) * | 2015-11-09 | 2021-05-26 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | がんの処置において有用なジヒドロイミダゾピラジノン誘導体 |
| TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商Ｈ 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
| CR20180553A (es) | 2016-04-22 | 2019-02-01 | Incyte Corp | Formulaciones de un inhibidor de lsd1 |
| CA3025586A1 (en) * | 2016-07-06 | 2018-01-11 | Imara, Inc. | Pde9 inhibitors for treatment of peripheral diseases |
| CN109843884B (zh) | 2016-10-18 | 2022-03-04 | H.隆德贝克有限公司 | 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮 |
| RS60716B1 (sr) | 2016-10-28 | 2020-09-30 | H Lundbeck As | Kombinovane terapije koje obuhvataju imidazopirazinone za lečenje psihijatrijskih i/ili kognitivnih poremećaja |
| MX2019004859A (es) | 2016-10-28 | 2019-06-20 | H Lundbeck As | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. |
| CN110325535A (zh) * | 2017-02-27 | 2019-10-11 | 詹森药业有限公司 | 经哌啶、吗啉或哌嗪取代的作为oga抑制剂的[1,2,4]-三唑[1,5-a]-嘧啶基衍生物 |
| MX2019014049A (es) * | 2017-05-26 | 2020-07-28 | Imara Inc | Metodos de fabricacion y uso de inhibidores de pde9. |
| KR20200013758A (ko) | 2017-06-08 | 2020-02-07 | 머크 샤프 앤드 돔 코포레이션 | 피라졸로피리미딘 pde9 억제제 |
| US11147275B2 (en) | 2017-11-23 | 2021-10-19 | Basf Se | Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi |
| MX2020012636A (es) | 2018-05-25 | 2021-01-29 | Imara Inc | Formas de monohidrato y cristalinas de 6-[(3s,4s)-4-metil-1-(pirim idin-2- ilmetil)pirrolidin-3-il]-3-tetrahidropiran-4-il-7h-imidazo [1,5-a]pirazin-8- ona. |
| WO2019243528A1 (en) * | 2018-06-20 | 2019-12-26 | Janssen Pharmaceutica Nv | Oga inhibitor compounds |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| BR112021003686A2 (pt) | 2018-08-31 | 2021-05-18 | Imara Inc. | inibidores de pde9 para tratar doença falciforme |
| JP2022527630A (ja) * | 2019-04-05 | 2022-06-02 | イマラ インク． | 鎌状赤血球症を治療するためのｐｄｅ９阻害剤 |
| TW202108585A (zh) * | 2019-05-07 | 2021-03-01 | 美商伊馬拉公司 | 用於治療地中海型貧血之pde9抑制劑 |
| WO2022036111A1 (en) * | 2020-08-13 | 2022-02-17 | Imara Inc. | Methods and compositions for treating sickle cell disease |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL135462A0 (en) | 1997-11-12 | 2001-05-20 | Bayer Ag | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
| WO2000043392A2 (de) | 1999-01-20 | 2000-07-27 | Arzneimittelwerk Dresden Gmbh | Verwendung von imidazo[1,5-a]-pyrido[3,2-e]-pyrazinonen als arzneimittel |
| PL370599A1 (en) | 2001-11-02 | 2005-05-30 | Pfizer Products Inc. | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors |
| HN2002000317A (es) * | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| GB2388111A (en) | 2002-05-01 | 2003-11-05 | Bayer Ag | Novel imidazotriazinone compounds |
| US20040220186A1 (en) * | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| BRPI0416118A (pt) | 2003-10-31 | 2007-01-02 | Pfizer Prod Inc | inibição da fosfodiesterase 9 como tratamento para estados relacionados com a obesidade |
| US7709468B2 (en) | 2005-09-02 | 2010-05-04 | Abbott Laboratories | Imidazo based heterocycles |
| TW200815436A (en) * | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| WO2008029589A1 (en) | 2006-09-08 | 2008-03-13 | Tokuyama Corporation | Method and equipment for producing group-iii nitride |
| EP2489667B1 (en) | 2006-12-13 | 2015-04-15 | ASKA Pharmaceutical Co., Ltd. | Quinoxaline derivative |
| CA2672591A1 (en) | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | Treating agent of uropathy |
| GEP20125405B (en) | 2007-05-11 | 2012-02-27 | Pfizer | Amino-heterocyclic compounds |
| DE102007032349A1 (de) | 2007-07-11 | 2009-01-15 | Bayer Healthcare Ag | Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| WO2011028820A1 (en) | 2009-09-02 | 2011-03-10 | Concert Pharmaceuticals, Inc. | Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds |
| WO2012040230A1 (en) | 2010-09-20 | 2012-03-29 | Envivo Pharmaceuticals, Inc. | Imidazotriazinone compounds |
| CA2861795C (en) | 2011-10-07 | 2018-12-04 | Eisai R&D Management Co., Ltd. | Pyrazoloquinoline derivative |
| IN2015DN02829A (OSRAM) * | 2011-10-10 | 2015-09-11 | Lundbeck & Co As H | |
| CN107082783B (zh) | 2012-01-26 | 2019-03-22 | H.隆德贝克有限公司 | 具有咪唑并三嗪酮骨架的pde9抑制剂 |
| EP2828262A4 (en) | 2012-03-19 | 2015-09-23 | Forum Pharmaceuticals Inc | IMIDAZOTRIAZINONVERBINDUNGEN |
-
2012
- 2012-10-09 IN IN2829DEN2015 patent/IN2015DN02829A/en unknown
- 2012-10-09 JP JP2015535994A patent/JP2015531401A/ja active Pending
- 2012-10-09 BR BR112015007731-5A patent/BR112015007731B1/pt active IP Right Grant
- 2012-10-09 AU AU2012323085A patent/AU2012323085B2/en active Active
- 2012-10-09 HK HK15111740.3A patent/HK1211023A1/xx unknown
- 2012-10-09 CN CN201710247417.1A patent/CN106905324B/zh active Active
- 2012-10-09 SG SG11201502728WA patent/SG11201502728WA/en unknown
- 2012-10-09 MX MX2019014982A patent/MX381326B/es unknown
- 2012-10-09 EP EP12772769.1A patent/EP2906562B1/en active Active
- 2012-10-09 EP EP16185105.0A patent/EP3121178B1/en active Active
- 2012-10-09 MX MX2015004422A patent/MX370433B/es active IP Right Grant
- 2012-10-09 US US14/434,308 patent/US9643970B2/en active Active
- 2012-10-09 MA MA37958A patent/MA37958B1/fr unknown
- 2012-10-09 CN CN201280076285.6A patent/CN104703987B/zh active Active
- 2012-10-09 CA CA2886885A patent/CA2886885C/en active Active
- 2012-10-09 WO PCT/EP2012/069936 patent/WO2013053690A1/en not_active Ceased
-
2015
- 2015-03-16 TN TNP2015000100A patent/TN2015000100A1/fr unknown
- 2015-03-19 IL IL237836A patent/IL237836A/en active IP Right Grant
-
2017
- 2017-03-08 US US15/452,827 patent/US9993477B2/en active Active
- 2017-03-20 AU AU2017201873A patent/AU2017201873C1/en active Active
- 2017-07-12 IL IL253448A patent/IL253448A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017201873C1 (en) | PDE9i with imidazo pyrazinone backbone | |
| EP3178820B1 (en) | Pde9- inhibitors with imidazo triazinone backbone | |
| TWI743401B (zh) | 吲哚甲醯胺化合物 | |
| JP2019507766A (ja) | 線維症の治療のための新規化合物及びその医薬組成物 | |
| CN111051309A (zh) | 可用作a2a受体拮抗剂的三唑并三嗪衍生物 | |
| WO2020085234A1 (ja) | モルヒナン誘導体 | |
| CN114222744B (zh) | 可用作IL-12、IL-23和/或IFNα反应调节剂的咪唑并哒嗪化合物 | |
| HK40019786A (en) | Triazolotriazine derivatives as a2a receptor antagonists | |
| HK1178149A1 (en) | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
| HK1178149B (en) | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |